Clinical Trials Logo

Resistant Hypertension clinical trials

View clinical trials related to Resistant Hypertension.

Filter by:

NCT ID: NCT03758196 Recruiting - Clinical trials for Resistant Hypertension

Renal Sympathetic Denervation From the Adventitia on Resistant Hypertension(RSDARH)

Start date: October 31, 2018
Phase: N/A
Study type: Interventional

As one of the most common chronic diseases,The adult prevalence of hypertension is approximately 26.4% at present and will rise to 29.2% by 2025.Renal sympathetic denervation from the intima of renal artery has emerged as a potential treatment for resistant hypertension. However, renal sympathetic nerve are mainly located in the adventitia,and there is no report on renal sympathetic denervation from the adventitia of renal artery.This study is a multicenter,randomized,single-blind study,and aimed to observe the safety and efficacy of radiofrequency ablation of the renal artery from the adventitia on the basis of laparoscopic techniques for patients with resistant hypertension.

NCT ID: NCT03541174 Recruiting - Clinical trials for Resistant Hypertension

A Research Study to Show the Effect of Aprocitentan in the Treatment of Difficult to Control (Resistant) High Blood Pressure (Hypertension) and Find Out More About Its Safety

Start date: June 18, 2018
Phase: Phase 3
Study type: Interventional

The purpose of the study is to show the blood pressure lowering effect of aprocitentan, a new drug, when added to other anti-hypertensive drugs of patients with difficult to control (resistant) high blood pressure (hypertension), and to show that blood pressure reduction is kept for long period of time.

NCT ID: NCT03540992 Recruiting - Clinical trials for Resistant Hypertension

Development of Diagnostic and Treatment Strategy for Resistant Hypertension

Start date: February 14, 2018
Study type: Observational

This study is a registry study to examine the clinical features, blood pressure control rate, and clinical prognosis of resistant hypertension in Koreans. This study will register patients with resistance hypertension in eight tertiary hospitals in Korea and follow up them for three years. The prognosis will be analysed according to etiologies, achieved blood pressure, and types of antihypertensive medication.

NCT ID: NCT03535532 Not yet recruiting - Clinical trials for Resistant Hypertension

Unilateral Laparoscopic Adrenalectomy for Resistant Hypertension in Patients With Adrenal Diseases

Start date: December 20, 2018
Phase: N/A
Study type: Interventional

ULARH is a 2-arm, prospective, open-labeled, multi-center randomized clinical trial.The purpose of this study is to compare the effectiveness of medical treatment and unilateral laparoscopic adrenalectomy for resistant hypertension in patients diagnosed with adrenal disease based on imaging tools.Relative ratio of end-point events occurence in three years is considered as primary outcome. Furthermore, we will exploit clinical factors which could indicate a favorable outcome in participants who accepted surgical treatment in this study.

NCT ID: NCT03424317 Recruiting - Clinical trials for Resistant Hypertension

Therapeutic Effect of Sodium Intake Reduction in Treatment Resistant Hypertension

Start date: January 1, 2018
Phase: N/A
Study type: Interventional

The aim of this study was to evaluate the therapeutic effect of sodium intake reduction by education in patients with resistant hypertension. The study was designed to maximize the compliance to antihypertensive agents and use optimal doses of antihypertensive agents including diuretics for 2 months before randomization. Patients will be assigned randomly to receiving (1) education of sodium intake reduction and exercise, or (2) education of exercise alone. Education of sodium intake reduction will be blinded to patients, and education of exercise will be provided to both group to blind the subjects. Daytime ambulatory blood pressure is adopted for diagnosis of resistant hypertension to avoid white-coat effect.

NCT ID: NCT03257488 Recruiting - Clinical trials for Sleep Apnea, Obstructive

Screening of Obstructive Sleep Apnea Syndrome in Patients With Resistant Systemic Arterial Hypertension: Pilot Study

Start date: April 2015
Phase: N/A
Study type: Interventional

This study evaluates the utility and reliability of Somnocheck micro Weinmann for obstructive sleep apnea syndrome (OSAS) screening in patients affected by resistant systemic arterial hypertension. Results are compared with a modified portable sleep apnea testing (type III portable monitoring: Somnocheck 2 Weinmann).

NCT ID: NCT03179800 Recruiting - Hypertension Clinical Trials

CALM- 2 - Controlling and Lowering Blood Pressure With the MobiusHD™

Start date: October 19, 2017
Phase: N/A
Study type: Interventional

The objective of this study is to evaluate the safety and effectiveness of the MobiusHD System in a prospective, randomized, double-blind, sham-controlled multi-center pivotal study.

NCT ID: NCT03090529 Recruiting - Clinical trials for Resistant Hypertension

The Role of Exercise Training in the Treatment of Resistant Hypertension

Start date: March 1, 2017
Phase: N/A
Study type: Interventional

The main purpose of this study is to assess whether exercise training reduces ambulatory blood pressure in patients with resistant hypertension. To accomplish these goals 60 patients with resistant hypertension will be recruited and randomized into exercise training or control groups and followed up for 6 months. The patients in the exercise group will participate in a 3-month outpatient program. The control group will receive usual medical care. At baseline, after the intervention and 3 months after the end of the intervention both groups will undergo several evaluations, including casual and ambulatory blood pressure, body composition, cardiorespiratory fitness, quality of life, arterial stiffness, autonomic function, and endothelial and inflammatory biomarkers.

NCT ID: NCT03071263 Completed - Hyperkalemia Clinical Trials

Spironolactone With Patiromer in the Treatment of Resistant Hypertension in Chronic Kidney Disease

Start date: February 13, 2017
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine if patiromer treatment in chronic kidney disease (CKD) subjects receiving spironolactone for the treatment of resistant hypertension will result in more persistent use of spironolactone through prevention of hyperkalemia and lead to improved blood pressure control compared with treatment with spironolactone alone (placebo).

NCT ID: NCT02926495 Withdrawn - Clinical trials for Resistant Hypertension

Subcutaneous Median Nerve Neuromodulation For Drug-Treatment Resistant Hypertension.

Start date: November 2016
Phase: N/A
Study type: Interventional

Hypertension is a serious public health issue, affecting approximately 30% of adults. Hypertension greatly contributes to the risk for heart disease and stroke, both among the top three leading causes of death in the Americas, Europe, and Asia. While most treated individuals with hypertension are controlled on medication, diet and exercise, an estimated 12% are resistant to conventional medical intervention. Alternative effective treatments are still needed for this hypertensive patient population to mitigate the risk and incidence of mortality and morbidity. This original Investigational Device Application is for a study intended to confirm the safety and efficacy of bilateral subcutaneous median nerve stimulation using the eCoin system to treat resistant hypertension. The eCoin device delivers electrical stimulation pulses to the median nerve from a small coin sized device placed under the skin of the distal anterior forearm. The implant delivers a weekly 30 minute treatment based on previous studies showing a long lasting and cumulative effect. The safety and efficacy of eCoin therapy has previously been demonstrated in a multinational, randomized, double-blind, sham-controlled study in New Zealand, Taiwan and Canada. This trial is a multi-center, prospective, double-blind, 1:1 randomized sham-controlled study of the safety and effectiveness of eCoin median nerve neuromodulation in subjects with drug-treatment resistant hypertension. The eCoin neuromodulation device will be implanted subcutaneously in the right and left forearms of patients with uncontrolled hypertension despite treatment with 3 or more antihypertensive agents. After a 4 week implant healing period, subjects will be 1:1 randomized into either a treatment or control group. One half of the subjects have their devices activated (treatment) and the other half undergo a sham activation (control) to maintain participant blinding to their treatment allocation. During the six months post-randomization, the eCoin is ON in the treatment group and OFF in the control group.